A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

Histologically or cytologically confirmed non-squamous NSCLC
Documented progression of disease (locally recurrent or metastatic) per investigator assessment following first-line treatment with 4-6 cycles of Bevacizumab plus a platinum doublet-containing chemotherapy regimen and a minimum of 2 cycles of Bevacizumab (monotherapy) maintenance treatment prior to first progression of disease
No treatment interruption of Bevacizumab treatment greater than 2 consecutive cycles (42 days) between the start of first-line treatment to start of Cycle 1 of second line treatment
Randomization within 4 weeks of progression of disease
At least one unidimensionally measurable lesion meeting RECIST v1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Participants with adequate hematological, liver, and renal function
Female participants must not be pregnant or breast-feeding. Female participants of childbearing potential and fertile male participants must agree to use a highly effective contraceptive during the trial and for a period of at least 6 months following the last administration of trial drug(s)

Exclusion Criteria:

Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component
Epidermal growth factor receptor (EGFR)-mutation-positive disease according to local laboratory testing
History of hemoptysis greater than or equal to (>/=) grade 2 within 3 months of randomization
History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding and active gastrointestinal bleeding
Major cardiac disease
Treatment with any other investigational agent within 28 days prior to randomization
Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen
Malignancy other than NSCLC within 5 years prior to randomization and evidence of any other disease that contraindicates the use of an investigational or SOC drug